Survival of 230 patients with AL amyloidosis treated with CyBorD according to cardiac stage based on cardiac biomarkers: NT-proBNP (cutoff 322 ng/L) and troponin cTnT (cutoff 0.035 ng/mL), or cTnI (cutoff 0.1 ng/mL). Stage I, normal biomarkers; stage II, one marker above the cutoff; stage IIIa: both markers above the cutoff but NT-proBNP ≤8500 ng/L; and stage IIIb: NT-proBNP >8500 ng/L. See Figure 1B in the article by Palladini et al that begins on page 612.

Survival of 230 patients with AL amyloidosis treated with CyBorD according to cardiac stage based on cardiac biomarkers: NT-proBNP (cutoff 322 ng/L) and troponin cTnT (cutoff 0.035 ng/mL), or cTnI (cutoff 0.1 ng/mL). Stage I, normal biomarkers; stage II, one marker above the cutoff; stage IIIa: both markers above the cutoff but NT-proBNP ≤8500 ng/L; and stage IIIb: NT-proBNP >8500 ng/L. See Figure 1B in the article by Palladini et al that begins on page 612.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal